Moderna files for emergency use of BA.4/BA.5 Omicron booster
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Gomez joins Moderna from Dentsply Sirona, where he served as Executive Vice President & Chief Financial Officer since August 2019
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Subscribe To Our Newsletter & Stay Updated